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Abstract
By using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting assays in the presence of
polyclonal antiserum raised against electrophoretically specific polypeptides of colorectal cancer nuclear polypeptides with
Mr of 35^40 kDa, we have identified p36 protein whose expression accompanies tumorigenesis of large intestine.
Immunological analysis of 35 nuclear protein preparations has indicated expression of p36 antigen in nine of 11 right-sided
(81.8%) and 21 of 24 (87.5%) left-sided colorectal tumor cases, but not in any control tissue samples. In this study, we have
identified p36 antigen in two colon tumor cell lines, i.e., SW620 and HT29 as well. Fractionation experiments based on
selective extraction of nuclei isolated from cancerous specimens, which enables their separation into chromatin, nuclear
matrix and its subfraction, i.e., internal and peripheral matrix have revealed the concentration of this particular antigen in the
internal matrix. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Colorectal cancer is a common disease in the in-
dustrialized Western Europe countries and the
United States [1,2]. This cancer is the second leading
cause of malignant deaths in Poland [3]. The patho-
genesis of colorectal cancer is of particular interest
for the complex and only partially understood inter-
action between environmental factors and genetic
background. The current model for colorectal carci-
nogenesis postulates a multistage progression involv-
ing an accumulation of gene mutations (APC, DCC,
K-ras, p53, DNA mismatch repair genes), alterations
in gene expression (c-myc, TGFL receptor), and chro-
mosome losses, during which regulation of cell
growth is disrupted [4^8]. Recently published data
indicate that mechanisms of colorectal tumorigenesis
may di¡er according to tumor location [9^11].
It is an accepted opinion that cancers in the prox-
imal colon are associated with intrinsic factors such
as bile acids and sex hormones, whereas distal can-
cers are more closely related to environmental factors
such as diet, cigarette smoking, and alcohol con-
sumption [8].
A cellular hallmark of the transformed phenotype
is an abnormal nuclear shape [12,13]. Nuclear struc-
tural alterations are commonly used as pathological
markers in transformation in many types of cancer.
Nuclear shape is thought to re£ect the internal nu-
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clear structure and processes, and is determined
mainly by the nuclear matrix (NM). This structure
organizes DNA into structurally and functionally in-
dependent domains [14,15]. Since this structure plays
an essential role in supporting most of nuclear func-
tions, i.e. replication, transcription, RNA metabo-
lism and transport, it has been postulated that during
carcinogenesis its components would be altered
[16,17].
The NM is the nonchromatin structural protein
and ribonucleoprotein network that is resistant to
nucleases, detergents and high-ionic strength bu¡ers
[14,15,18,19]. The resulting structures which retain
the overall shape of nuclei, are mainly composed of
non-histone proteins and variable amounts of RNA
and DNA [18^24]. Ultrastructural investigations
have revealed that the NM can be divided into two
compartments, i.e. internal matrix (internal network
with residual nucleoli described as: NMi) which con-
tains residual nucleoli, and peripheral matrix (resid-
ual lamina-pore complex: NMp) composed of resid-
ual lamina^pore complex [19,23,24]. It has shown
that morphological and functional properties of the
NM vary depending on the manner employed for its
isolation [19,22^24]. Several studies have shown that
an incubation of isolated nuclei near physiological
temperature of 37‡C stabilizes the NMi and nucleo-
lar remnants against the dissociation agents used
during the extraction procedure [19,22,25].
Numerous studies led to the conclusion that the
changes in the pattern of gene expression which oc-
cur during cell neoplastic transformation can be in-
tuitively ascribed to the perturbation of interactions
between chromatin and proteinaceous NM [26^28].
The precise analysis of protein composition changes
which the NM undergoes during cell transformation
has been lately reported [29^32]. Thus, NM proteins
present in cancer cells but not in their normal coun-
terparts have been described in a numerous organs
such as bladder, breast, colon, uterus, prostate and
bone [33^39].
In this study we have focused on the protein with a
Mr of 36 kDa whose expression is observed in colon,
stomach and lung tumor cell nuclei but not in nor-
mal tissue [40,41]. By polyclonal antiserum raised
against a electrophoretically speci¢c nuclear polypep-
tide-zone (35^40 kDa) from colon adenocarcinoma
(hepatic £exure) we have analyzed the presence of
cancer-speci¢c component(s) among nuclear proteins
from colorectal tumors appearing in right- and left-
sided large intestine as well as in the nuclear fraction
of human colon tumor cell lines. Using this antise-
rum we have veri¢ed the presence of this particular
antigen(s) among colonic tumor nuclear fractions:
chromatin and NM, and subfractions of the latter,
i.e., NMi with nucleolar remnants and NMp.
2. Materials and methods
2.1. Patients
Fresh human tumor and normal tissue samples
were obtained from 35 patients with colorectal carci-
nomas undergoing surgical resection at the Surgical
Oncology Clinic of Medical University of 6o¤dz¤, Po-
land. The patients comprised 16 women and 19 men,
with mean age 60.4 years (range 18^77 years). The
location of the tumor in these patients was as fol-
lows: 11 in right-sided (including the cecum, ascend-
ing and transverse colon) and 24 in left-sided colon
(descending, sigmoid colon and rectum). The tumors
were staged according to Dukes classi¢cation.
2.2. Colon tumor cell line cultures
Cells HT29 derived from a 44 year old female with
colon adenocarcinoma were obtained from the Deut-
sche Krebsforschungzentrum Heidelberg, Germany.
Cells SW620 isolated from a lymph node metastasis
of grade III-IV adenocarcinoma of the colon of a 51
year old male were purchased from ECACC (Cat.
No. 87051203, Salisbury, UK).
Cells were grown in OptiMEM medium supple-
mented with 5% fetal bovine serum and glutamine
(2 mM), at 37‡C in 5% CO2, 95% humidi¢ed air.
Cells were passaged after reaching subcon£uency, us-
ing 0.5% trypsin/0.02% EDTA solution (all reagents
from Gibco, BRL, Life Technologies, UK), and
seeded at the density 3U104 cells/ml in 25 ml or 75
ml £asks (Falcon, Becton Dickinson, Heidelberg,
Germany). All cells under investigation were
screened for Mycoplasma contamination by using
Mycoplasma Detection kit enzyme immunoassay
(Boehringer Mannheim) and were found to be neg-
ative. For the experiment, cells were collected, from
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the full monolayer, by mechanical means (scraping)
and washes twice with Ca2, Mg2-free PBS saline
solution.
2.3. Preparation of nuclei
The samples of normal or cancerous material were
minced by ¢ne dissection and homogenized (4‡C) in
0.25 M sucrose, 5 mM MgCl2, 0.5% Triton X-100,
1 mM phenylmethylsulfonyl £uoride (PMSF), 50 mM
Tris^HCl (pH 7.4), followed by centrifugation of the
homogenate at 800Ug for 10 min. The centrifugation
was repeated and the crude nuclei was puri¢ed by the
sucrose method [42].
2.4. Isolation of the NM
NM preparations were isolated by the modi¢ed
method of Belgrader et al. [19]. The nuclei prepared
by sucrose technique were washed twice in TM2 bu¡-
er: 10 mM Tris^HCl, pH 7.4, 2 mM MgCl2, 1 mM
PMSF and subsequently centrifuged at 1000Ug (10
min, 4‡C). The nuclei were resuspended in TM2 bu¡-
er and stabilized by incubation for 1 h at 37‡C.
MgCl2 was added to the nuclei in TM2 bu¡er to a
¢nal concentration of 5 mM. Then nuclei suspension
was digested with DNase I (Sigma) (0.2 mg DNase
I/1 mg DNA) for 20 min at 37‡C. The digestion was
stopped by placing the probe on ice. A stock solution
of 2 M ammonium sulfate (AS) was slowly (drop-
wise) added to a ¢nal concentration of 0.25 M AS.
The nuclei suspension was then twice extracted in a
glass^te£on homogenizer with 0.25 AS in TM 0.2
bu¡er: 10 mM Tris^HCl, pH 7.4, 0.2 mM MgCl2,
1 mM PMSF to remove the soluble chromatin pro-
teins, and centrifuged at 2000Ug for 15 min (4‡C).
The NM pellet was resuspended in TM 0.2 bu¡er
and used immediately or stored at 370‡C.
2.5. Fractionation of nuclei
For fractionation of cell nuclei the combination of
Stuurman et al.’s [22] and Payrastre et al.’s [43] tech-
niques were employed. Nuclei prepared by the su-
crose method were washed twice in STM bu¡er
(0.25 M sucrose, 50 mM Tris^HCl pH 7.4, 5 mM
MgCl2, 1 mM PMSF). For the preparation of NMi
nuclei prepared as above were ¢rst stabilized by in-
cubation for 1 h at 37‡C with 0.5 mM sodium tetra-
thionate (NaTT) in STM bu¡er. Nuclei were washed
three times with STM and digested with DNase I
(0.2 mg enzyme/1 mg DNA) for 20 min at 37‡C.
AS was added dropwise to a ¢nal concentration of
0.25 M AS. After extraction of AS-soluble chromatin
proteins on ice the NM was pelleted at 2000Ug for
10 min. Supernatant containing AS fraction was dia-
lyzed against water (several changes). NM pellet was
resuspended and incubated in STM bu¡er containing
0.25 M AS and 40 mM dithiothreitol for 20 min at
37‡C. The solubilized NMi was cleared from NMp by
centrifugation at 10 000Ug for 10 min. The super-
natant was dialyzed against 10 mM ammonium ace-
tate (pH 7.4) with several changes of acetate and
stored lyophilized. The NMp was washed with 10
mM Tris^HCl, pH 7.4, 0.2 MgCl2, 1 mM PMSF
and used immediately or stored frozen at 370‡C.
The pellet of NM before fractionation on NMi
and NMp was used for comparison studies.
2.6. Antiserum production
Rabbit polyclonal antiserum was raised against
electrophoretically speci¢c nuclear polypeptides
with a molecular mass of 35^40 kDa separated
from adenocarcinoma of colon (hepatic £exure) in
the course of preparative electrophoresis in sodium
dodecyl sulfate (SDS)-polyacrylamide slab gel. The
polypeptide-zone with an appropriate molecular
mass was excised from the gel, homogenized in
PBS (145 mM NaCl^10 mM phosphate bu¡er, pH
7.4), combined with the complete Freund’s adjuvant
(1:1, v/v, Miles Biochem.), and injected intrader-
mally. Thereafter, booster injections were given at
weekly intervals for 4 weeks. A total amount of ap-
proximately 200 Wg of the antigen was injected intra-
dermally. The rabbits were bled 1 week after the ¢nal
injection and the serum was assayed for antibodies
using immunoblotting technique. The rabbits were
bled prior to the antigen injection, and the serum
was used for control studies.
2.7. One-dimensional SDS-polyacrylamide gel
electrophoresis (SDS-PAGE)
Samples were mixed with 0.9 vol. of solubilizing
bu¡er (10% glycerol, 4% SDS, 25 Wg pyronin Y, 125
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mM Tris^HCl, pH 6.8, 1 mM PMSF), with 0.1 vol.
of 2-mercaptoethanol, and heated in boiling water
for 5 min. The PAGE was performed as described
by Laemmli [44] at 15 mA slab until the pyronin Y
marker reached the end of the 3.0% stacking gel and
then at 30 mA/slab in the 11.2% resolving gel until
the marker dye reached the bottom of the gel. About
20 and 500 Wg of protein were loaded per slot in the
case of analytical or preparative electrophoresis, re-
spectively. The slab gels were stained with silver ni-
trate by the method of Wray et al. [45] or Coomassie
brilliant Blue R-250 method [46]. Mr was determined
by comparing the mobilities of proteins to those of
known molecular mass standards (Sigma). The pro-
teins used as standards were: myosin (205 kDa),
L-galactosidase (116 kDa), L-phosphorylase (97
kDa), bovine serum albumin (66 kDa), ovalbumin
(45 kDa), carbonic anhydrase (30 kDa), soybean
trypsin inhibitor (20.1 kDa), and K-lactalbumin
(14.2 kDa).
2.8. Two-dimensional PAGE
Two-dimensional electrophoresis was carried out
according to the method of O’Farrell [47] as modi¢ed
by Cupo et al. [48]. The ¢rst-dimensional equilibra-
tion isoelectrofocusing gel containing a 2.0% total
carrier ampholyte mixture (composed of pH range
4.0^6.5, 6.5^9.0 and 3.0^10.0). The ¢nal acrylamide
concentration was 4.0% with a cross-linking of
2.5% N,NP-methylene-bis-acrylamide. The detergent
present in the gel was 0.025 M 3-[3-cholamido-prop-
yl]-dimethylammonio-1-propanesulfonate (CHAPS).
Proteins were solubilized in 8.0 M urea, 2.0% carrier
ampholytes, 0.065 M dithiothreitol, 0.5% Nonidet
P-40, 0.065 M CHAPS and samples of about 200
Wg were overlaid on the gels. The gels were electro-
phoresed for 14 h at 300 V and for 2 h at 400 V. The
electrolyte solutions were 0.02 M NaOH (cathode)
and 0.01 M H3PO4 (anode). The pH of the blank
gels was measured at 0.5 cm intervals in 0.01 M
KCl using a Beckman pH-meter. After isoelectric
focusing, the gels were equilibrated for 30 min in
10.0% glycerol, 5.0% 2-mercaptoethanol, 2.3% SDS,
and 0.0625 M Tris^HCl at pH 6.8. Electrophoresis in
second dimension was carried out on a 8.0% polyac-
rylamide gel according to Laemmli [44].
2.9. Immunoblotting assays
Electrophoretically separated proteins were blotted
onto Immobilon P according to the method of Tow-
bin et al. [49]. For immunodetection of antigen im-
mobilized on membrane the alkaline-phosphatase
technique was performed. The ¢lters were incubated
for 1 h at room temperature in 0.5% non-fat dry milk
in TBS (10 mM Tris^HCl, pH 7.5, 150 mM NaCl) to
saturate the nonspeci¢c protein binding sites. Immo-
bilon P ¢lters were then incubated with primary anti-
serum at 1:150 dilution in TBS^0.5% non-fat dry
milk overnight in cold room. After washing several
times in TBS containing 0.05% Tween 20 (TBST)
¢lters were incubated with goat anti-rabbit immuno-
globulin conjugated with alkaline phosphatase (Sig-
ma) at 1:6000 dilution in TBS^0.5% non-fat dry milk
for 2 h at room temperature. After washing with
TBST speci¢c antigen^antibody interactions were vi-
sualized by incubation with substrate solution (0.30
mg/ml of nitro blue tetrazolium and 0.15 mg/ml of 5-
bromo-3-indolyl phosphate in 100 mM Tris^HCl,
100 mM NaCl and 5 mM MgCl2, pH 9.5), prepared
according to the method of Leary et al. [50].
2.10. Analytical procedures
Protein was estimated by the method of Lowry et
al. [51] and DNA was determined spectrophotometri-
cally.
3. Results and discussion
Epidemiologic and genetic studies suggest that the
mechanisms of colorectal tumorigenesis may di¡er
according to tumor location [8,11,52,53]. It is worth
noting that countries in which the incidence of co-
lonic tumor is high have a relatively higher propor-
tion of left-sided tumors whereas, countries in which
the incidence is lower reveal a greater proportion of
right-sided tumors.
Previous results from our laboratory [40] demon-
strated that during colorectal carcinogenesis speci¢c
expression of some proteins from four cellular frac-
tions, i.e. nuclear, mitochondrial, microsomal and
cytosolic took place. Our interest is focused on nu-
clear proteins from cancerous and normal colon
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since the diversity in their electrophoretic patterns is
expressed to a signi¢cant extent. As it was docu-
mented by SDS-PAGE, gel patterns of nuclear pro-
teins from both normal and colorectal cancer sam-
ples showed many common constituents. However,
some di¡erences mainly among polypeptides with a
Mr of 21^30; 30^32; 35^40; 49^54 and 63^69 kDa
were observed (Fig. 1). The components with a Mr of
23, 25, 36 and 38 kDa seem to be colorectal cancer-
associated. Electrophoretic analysis of nuclear pro-
teins isolated from 35 cancer samples obtained
from di¡erent anatomic regions of large intestine
show reproducible patterns, with slightly quantitative
di¡erences, mainly in the region with a Mr of 35^40
kDa.
Since some di¡erences were found between nuclear
proteins of normal and colorectal cancer specimens
we have extended analysis of their speci¢city by two-
dimensional PAGE. A comparison of two-dimen-
sional electrophoretic behavior of proteins from nor-
mal and tumor nuclear fraction revealed their com-
plexity and diversities in their quantitative and
qualitative representation (Fig. 2). The predominant
spots in the colon tumor nuclei fraction were ob-
served in the area of two-dimensional gels with Mr/
pI of 44^48/5.3^6.0, 58^64/5.3^5.5 and 60^68/5.7^
7.2; whereas in normal nuclei, with Mr/pI of 44^48/
5.6^6.3, 50^59/5.3^6.3, 70^85/5.4^6.3 and 115^140/
5.6^6.2. Some components distributed in the area
of gels with low Mr, i.e., of 28^40 kDa as well as
with high Mr, i.e., of 65^70 and 120^130 kDa ap-
peared to be speci¢c for malignant tissue. Two spots
with a Mr of 36 kDa located in the area of gels
corresponding to pI 5.3 and 5.8 were detected only
in tumor colon specimens. They represent probably
the isoforms of p36 protein. It should be emphasized
that the sensitive method of protein detection with
Fig. 2. High resolution two-dimensional gel electrophoresis of
nuclear proteins from normal (I) and tumor (II) specimens of
the rectum followed by silver nitrate staining [45]. Isoelectric fo-
cusing (IFPA) in 4.0% polyacrylamide is shown on the abscissa,
and SDS-PAGE in 8.0% polyacrylamide is shown on the ordi-
nate. The parentheses [] indicate quantitative or qualitative
polypeptide di¡erences, and yy two spots of polypeptide with
Mr 36 kDa.
Fig. 1. SDS-PAGE of nuclear proteins from normal (I) and tu-
mor (II) specimens of the anus stained with silver nitrate [45].
The symbol [d] indicates quantitative or qualitative polypeptide
di¡erences. Arrows show the positions of molecular mass stand-
ards: myosin (205 kDa), L-galactosidase (116 kDa), L-phos-
phorylase (97 kDa), bovine serum albumin (66 kDa), ovalbu-
min (45 kDa), carbonic anhydrase (30 kDa), soybean trypsin
inhibitor (20.1 kDa), and K-lactalbumin (14.2 kDa).
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silver nitrate often produced spots with shades of
yellow or light brown visible on original gels but
indistinguishable on the black-and-white photograph
(i.e., the components with Mr/pI 28^40/5.3^6.0 in the
case of tumor nuclear fraction).
Electrophoretic diversity of nuclear proteins from
normal and cancerous colon especially with a Mr of
35^40 kDa was further explored by immunological
assays. Rabbit polyclonal antiserum was raised
against colon adenocarcinoma (hepatic £exure) nu-
clear polypeptides with a Mr of 35^40 kDa, sepa-
rated by preparative SDS-PAGE. The speci¢city of
obtained serum was veri¢ed by Western blotting
technique in the presence of adenocarcinoma and
normal colon nuclear proteins and also with preim-
mune serum (Fig. 3a). Fig. 3b demonstrates the pan-
el of immunoblot assays of nuclear proteins from
normal and cancer specimens of di¡erent anatomic
regions of large intestine. In Fig. 3b (BP)is shown
also an example of SDS-PAGE distribution of nu-
clear proteins obtained from normal and tumor sig-
moid colon followed by Coomassie brilliant Blue R-
250 staining.
It was noticed that obtained antiserum cross-re-
acted with most of the tumor nuclear protein prepa-
rations, i.e., 30 of 35 (85.7%) but not with those from
normal tissue. The above antiserum recognizes the
antigen with a Mr of 36 kDa (p36), and in some
cases also a component with a Mr of 32 kDa (p32).
Nonspeci¢c cross-reaction with high molecular
weight components can be observed sometimes while
no cross-reaction with preimmune serum was seen.
In studies performed until now p36 nuclear antigen
was detected in nine of 11 (81.8%) and 21 of 24
(87.5%) of right- and left-sided tumors, respectively.
The frequency of p36 expression in right-sided colon
tumors is slightly lower than that observed in left-
sided tumors. A higher degree of p36 immunostain-
ing in left-sided tumors is probably caused by the
fact that in these anatomic regions of large intestine
more aggressive tumors are developed [10,11,52,53].
Our previous data have revealed [41] that the pro-
gression of colorectal cancer classi¢ed by Dukes stag-
ing was accompanied by the increase of this partic-
ular antigen. Since colorectal cancers consist of a
usually heterogeneous population of cells, the nu-
clear fraction was also isolated from tumor cell lines
derived from epithelial colon adenocarcinomas, i.e.,
Fig. 3. Immunoblot analysis of nuclear protein fraction from normal (I) and tumor (II) specimens of di¡erent large intestine anatomic
regions. (a) Western blot analysis of nuclear proteins from normal and adenocarcinoma of colon (hepatic £exure) in the presence of
rabbit serum (dilution 1:150) before immunization (pre-immunized; pI) and after immunization (immunized; I) with nuclear polypep-
tides with Mr of 35^40 kDa from adenocarcinoma of colon (hepatic £exure). (b) Western analysis of nuclear proteins of normal and
tumor specimens obtained from ascending colon (A), sigmoid colon (B), and rectum (C) in the presence of polyclonal antiserum (dilu-
tion 1:150) raised against electrophoretically speci¢c nuclear polypeptides with a Mr of 35^40 kDa from adenocarcinoma of colon
(hepatic £exure). SDS-PAGE of nuclear proteins from normal and tumor specimens of sigmoid colon (BP) stained with Coomassie
brilliant Blue R-250 is included. Arrows indicate the position of p36 polypeptide.
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HT29, and SW620 (Fig. 4a,b). It was found that the
available serum recognized p36 nuclear antigen in
above tumor cell lines, however its concentration
showed some quantitative di¡erences. Considerably
elevated expression of p36 antigen was observed in
nuclear fraction originating from SW620 cell line
which is characterized by high potential to form
metastasis (Fig. 4a). The obtained data con¢rmed
that this particular antigen appears during colorectal
tumorigenesis and is not a result of contamination by
stromal cells or in£ammatory cell in¢ltration.
Nuclear structural alterations are also prevalent in
cancerous cells, they are commonly used as markers
of transformation for many types of cancer
[12,24,25,33^39]. It is generally accepted that mor-
phologic changes in nuclear shape and size during
carcinogenesis may re£ect changes in the protein
composition of the NM [12,26^28]. Several laborato-
ries have shown alterations in NM protein expression
during normal cell progression toward malignant
phenotype [30^39]. Since the NM plays a central
role in maintenance of gene expression and chroma-
tin remodeling during transformation of cells we
have concentrated on studies of colorectal cancer-
speci¢c p36 antigen within nuclear subfractions. In
initial experiments we have obtained nuclear matrices
from normal and colorectal cancer samples by the
modi¢ed method of Belgrader et al. [19] from nuclei
incubated for 1 h at 37‡C. This method eliminated
the use of high salt extraction with 1.6^2.0 M NaCl
of histones and other soluble components of cell nu-
clei during NM isolation. For this purpose it em-
ployed a milder extraction agent, i.e., 0.20^0.25 M
AS. As it was shown by Western blotting assays the
antiserum raised against adenocarcinoma nuclear
polypeptides with a Mr of 35^40 kDa stained p36
antigen in 13 of 13 NM preparations isolated from
colorectal tumor specimens, but not in any normal
colonic samples (Fig. 5a).
In further studies we have analyzed in more detail
the association of p36 antigen with nuclear subfrac-
tions of colorectal tumor samples. By a selective ex-
traction the nuclei can be dissected in the chromatin
fraction and the NM. The nuclear subfraction ob-
Fig. 5. Immunoblot analysis of NM (a) and nuclear subfractions (b) from normal and adenocarcinoma of the rectum. (a) Western
blot analysis of NM proteins from normal (I) and tumor (II) specimens isolated by Belgrader et al. [19] method. (b) Western blot
analysis of nuclear subfractions, i.e., NM, and chromatin (AS) from tumor specimens isolated according to Stuurman et al. [22] and
Payrastre et al. [43]. Immunodetection was performed in the presence of polyclonal antiserum (dilution 1:150) raised against electro-
phoretically speci¢c polypeptides with a Mr of 35^40 kDa from adenocarcinoma of colon (hepatic £exure). (c) Electrophoretic pattern
of NM, NMi, NMp, and AS nuclear subfractions stained with Coomassie brilliant Blue R-250. Arrows indicate the position of p36
polypeptide.
Fig. 4. Immunoblot (a) and SDS-PAGE (b) analysis of nuclear
proteins from tumor cell lines HT29 and SW620. Western blot
analysis was done in the presence of polyclonal antiserum
raised against electrophoretically speci¢c nuclear polypeptides
with a Mr of 35^40 kDa from adenocarcinoma of colon (hep-
atic £exure). Gels after SDS-PAGE were stained with Coomas-
sie brilliant Blue R-250. Arrows indicate the position of p36
polypeptide.
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tained during extraction of DNaseI treated puri¢ed
nuclei (stabilized for 1h at 37‡C) with 0.25 M AS
bu¡ered solution constitutes chromatin fraction.
The NM can be further separated biochemically
into the NMi and the NMp by treatment with reduc-
ing agent, i.e. dithiothreitol [22,23,43]. Immunodetec-
tion of p36 antigen in obtained colorectal tumor nu-
clear subfractions is demonstrated in Fig. 5b. Used
antiserum stains p36 band in unfractionated NM and
slightly also in chromatin fraction. p36 antigen is
clearly enriched in the IM but absent in the NMp.
This observation seems to be interesting since just
this NM substructure is associated with actively tran-
scribed genes and serve as site for processing and
transport of heterogeneous nuclear RNA [18,24,54^
56].
Generally, the NM appears to be fundamentally
involved in transcription regulation, which presum-
ably includes alteration in the normal cellular pheno-
type as a consequence of cancer development. The
precise analysis of protein composition changes
which the NM undergoes during neoplastic transfor-
mation has up to now been limited to only few sys-
tems [26,31^39]. In 1994 Keesee et al. [36] ¢rst de-
scribed six NM proteins expressed in
adenocarcinoma of the colon that were absent in
normal colonic tissue. Recently, speci¢c NM proteins
have been described in colon adenocarcinoma and
ulcerative colitis, which is recognized as a pre-neo-
plastic state of the colon [57,58].
Colorectal cancer-speci¢c p36 antigen detected in
our experiments in unfractioned nuclei and dominant
in the IM appears to be di¡erent from the above
described proteins [36,57,58]. At this time, it is di⁄-
cult to determine its possible function. Expression of
this particular polypeptide in NM and also in chro-
matin suggests the dynamic status of p36 in cell nu-
clei and possible regulatory function. Expression of
p36 antigen may be related to alterations in genetic
or molecular signaling pathways, common in the de-
velopment of colorectal cancer. This protein may be
considered as a potential marker for the colorectal
tumorigenesis.
Obtained results extend similar ¢ndings of cancer-
associated NM protein(s) in neoplasms of di¡erent
organs [26,33^39,57,58] and suggest that polypep-
tides of this important nuclear substructure may rep-
resent a new cancer biomarker with e⁄ciency for the
detection and/or in the management of some types of
cancer.
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